To a problem of the markers of vessels wall at EPH-gestosis

Abstract

Content in blood of markers of damage of a vessel wall (factor Willebrand, tissue of a catalyst plasminogen, cells circulating in blood endothelium), and also intravessel an aggregate platelet and uterine - placental bloodcurrent at 205 patients, among which woman with physiological current of pregnancy and with EPH-gestosis of a various degree of weight is investigated. The patients with nephropathy and preeclampsy were divided into groups depending on a method of treatment.

The 46 pregnant with EPH-gestosis of a various degree of weight was carried by clofelin in a daily doze 0,00015-0,0003 g during 7-10 days, 42 women therapy (the course doze 25,5-27 g of dry substance) is spent magnesium, 59 pregnant received clofelin and magnesium therapy in the above-stated dozes. The group of comparison formed 38 patients.

It was shown the important value of a research of markers of damage endothelium for diagnostics, definition of a degree of weight and control for efficiency of therapy pregnant with EPH-gestosis. Clofelin and magnesium, used for treatment of pregnant with EPH-gestosis as is independent, and in a combination, have endotheliumprotection operation, as reduce in authentic decrease of a content in blood of a marker of vessel's disorders of circulating cells endothelium, and also reduce intravessel an aggregate of platelets and improve uterine-placental bloodcurrent.

Keywords

gestosis / Willenbrand factor / tissue plasminogen activator / endothelium / aggregation / uteroplacental blood flow

References

[1] Гапковска я Э.Л., Яковлева Л. В., Шифман Е.М. Антигипертензивная терапия при тяжелых формах артериальной гипертензии, обусловленной беременностью // Достижения, успехи, перспективы родильного дома № 1 города Петрозаводска: Сб. науч. тр. - Петрозаводск: "ИНКА", 1993.-С.15-17.

[2] Зильбер АЛ., Шифман ЕМ., Вартанов В. Я. Терапия при тяжелых формах артериальной гипертензии, обусловленной беременностью //Анест. и реаним.-1993.-№ 3.-С.37-40.

[3] Меллина И.М., Тараховский М.А., Гутман Л.Б., Зайцева НЕ. Особенности лечения гипертонической болезни клофелином у беременных// Врач, дело. -199 1.-№7.-С.36-39.

[4] Петрищев Н.Н. Тромборезистентность сосудов.-СПб: 'АНТ-М', 1994.-130 с.

[5] Репина М.А., Конычева Е.А. Состояние гемостаза у беременных с гестозом// Актуальные вопросы службы крови и трансфузиологии: Тезисы докладов Российской конференции 6-8 июня 1995г., Санкт- Петербург.-Санкт-Петербург, 1995. - С. 157-159.

[6] Серов В.Н., Макацария АД. Тромбоэмболические и геморрагические осложнения в акушерстве. -М. -.Медицина, 1987. -288с.

[7] Caron С., Goudeman J, Morey А., Beage D et al. Are haemostatic and fibrinolytic parameters preditons of preeclampsia in prègnancy-associated hypertension?// Thromb. Haemost.- 1991.-Vol.66, №4.-P. 410-414.

[8] Davis J. W., Shelton L, Eigenberg D.A., Hignite C.E. et al. Effects of tobacco and non-tobacco cigarette smoking on endothelium and platelets // Clin. Pharmacol. Ther.-1985.-Vol.37.-P.529- 533.

[9] Krege J.h., KatzzV.L. A proposed relotionship between vasopressinase altered vasopressin and preedompsia// Med. Hypotheses. -1990. - Vol. 31,№4. - P.283-287.

[10] Ravn H.B.,Vissinger H, Kristensen S.D., Husted S.E. Effect of intravenous magnesium infusion on platelet function and fibrinolysis //Thromb. Haemost. - 1995.-Vol.73, №6.-P. 1449.

[11] Sinzinger H., VirgoTmi I., Fitsha P., Rauscha F. et al. Stabilization of endothelial lining and decrease in circulating endothelial cells one mechanism underlying the clinical action of PGE1?// Br. J. Clin. Pharmacol.- 1988.-Vot.25.-P.775-776.

RIGHTS & PERMISSIONS

Eсо-Vector